Somatostatin receptor 2A expression in von Hippel-Lindau-related hemangioblastomas.
hemangioblastomas
somatostatin
somatostatin expression
von Hippel‐Lindau
Journal
Cancer
ISSN: 1097-0142
Titre abrégé: Cancer
Pays: United States
ID NLM: 0374236
Informations de publication
Date de publication:
02 Jun 2024
02 Jun 2024
Historique:
revised:
01
04
2024
received:
02
01
2024
accepted:
03
05
2024
medline:
2
6
2024
pubmed:
2
6
2024
entrez:
2
6
2024
Statut:
aheadofprint
Résumé
Central nervous system hemangioblastomas are the most prevalent manifestation of von Hippel-Lindau (VHL) disease and remain the main cause of mortality. Surgical resection is the primary treatment strategy, but is not always possible, and should be used as restrictively as possible. There is an unmet need for less invasive treatment strategies, such as targeted therapy. Expression of somatostatin receptor 2A (SSTR2A) in VHL-related hemangioblastomas has been described earlier, but the extent of expression in a larger population has yet to be determined. The authors hypothesize that a substantial subset of VHL-related hemangioblastomas show SSTR2A expression, which may serve as a potential new treatment target. Patients who were surgically treated for a VHL-related hemangioblastoma from 1990 until 2021 at the UMC Utrecht were included. Clinical data was derived from a clinical database. Tissue samples were histopathologically examined with use of hematoxylin and eosin staining, and immunohistochemical analysis of SSTR2A expression was performed. Forty-three tissue samples were obtained from 26 patients. Nine showed strong positivity for SSTR2A expression, whereas 13 showed moderate and 15 sparse expression. Three samples showed no expression of SSTR2A. The distribution showed right-skewedness favoring a strong expression. SSTR2A expression colocalized with endothelial markers and not with stromal cells. Additionally, within-patient variability for SSTR2A expression was described in 14 patients. SSTR2A is expressed in varying degrees in the majority of VHL-related hemangioblastomas. Future treatment with somatostatin analogues or even peptide receptor radionuclide treatment may be considered for SSTR2A-positive cases.
Sections du résumé
BACKGROUND
BACKGROUND
Central nervous system hemangioblastomas are the most prevalent manifestation of von Hippel-Lindau (VHL) disease and remain the main cause of mortality. Surgical resection is the primary treatment strategy, but is not always possible, and should be used as restrictively as possible. There is an unmet need for less invasive treatment strategies, such as targeted therapy. Expression of somatostatin receptor 2A (SSTR2A) in VHL-related hemangioblastomas has been described earlier, but the extent of expression in a larger population has yet to be determined. The authors hypothesize that a substantial subset of VHL-related hemangioblastomas show SSTR2A expression, which may serve as a potential new treatment target.
METHODS
METHODS
Patients who were surgically treated for a VHL-related hemangioblastoma from 1990 until 2021 at the UMC Utrecht were included. Clinical data was derived from a clinical database. Tissue samples were histopathologically examined with use of hematoxylin and eosin staining, and immunohistochemical analysis of SSTR2A expression was performed.
RESULTS
RESULTS
Forty-three tissue samples were obtained from 26 patients. Nine showed strong positivity for SSTR2A expression, whereas 13 showed moderate and 15 sparse expression. Three samples showed no expression of SSTR2A. The distribution showed right-skewedness favoring a strong expression. SSTR2A expression colocalized with endothelial markers and not with stromal cells. Additionally, within-patient variability for SSTR2A expression was described in 14 patients.
CONCLUSION
CONCLUSIONS
SSTR2A is expressed in varying degrees in the majority of VHL-related hemangioblastomas. Future treatment with somatostatin analogues or even peptide receptor radionuclide treatment may be considered for SSTR2A-positive cases.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Author(s). Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society.
Références
Lonser RR, Glenn GM, Walther M, et al. Von Hippel‐Lindau disease. Lancet. 2003;361(9374):2059‐2067. doi:10.1016/S0140‐6736(03)13643‐4
van Leeuwaarde RS, Ahmad S, van Nesselrooij B, Zandee W, Giles RH. Von Hippel‐Lindau Syndrome; GeneReviews® [Internet]. University of Washington, Seattle; 2024: 1993‐2024.
Wanebo JE, Lonser RR, Glenn GM, Oldfield EH. The natural history of hemangioblastomas of the central nervous system in patients with von Hippel‐Lindau disease. J Neurosurg. 2003;98(suppl 1):82‐94. doi:10.3171/jns.2003.98.1.0082
Ordookhanian C, Kaloostian PE, Ghostine SS, Spiess PE, Etame AB. Management strategies and outcomes for VHL‐related craniospinal hemangioblastomas. J Kidney Cancer VHL. 2017;4(3):37‐44. doi:10.15586/jkcvhl.2017.90
Sizdahkhani S, Feldman MJ, Piazza MG, et al. Somatostatin receptor expression on von Hippel‐Lindau‐associated hemangioblastomas offers novel therapeutic target. Sci Rep. 2017;7(1):40822. doi:10.1038/srep40822
Shell J, Tirosh A, Millo C, et al. The utility of 68Gallium‐DOTATATE PET/CT in the detection of von Hippel‐Lindau disease associated tumors. Eur J Radiol. 2019;112:130‐135. doi:10.1016/j.ejrad.2018.11.023
Patel M, Jha A, Antic T, et al. 68Ga‐DOTATATE avid metastatic vertebral renal cell carcinoma in the setting of von Hippel‐Lindau syndrome. Nucl Med Mol Imaging. 2022;56(5):259‐262. doi:10.1007/s13139‐022‐00761‐7
Papadakis GZ, Millo C, Sadowski SM, Bagci U, Patronas NJ. Epididymal cystadenomas in von Hippel‐Lindau disease showing increased activity on 68Ga DOTATATE PET/CT. Clin Nucl Med. 2016;41(10):781‐782. doi:10.1097/RLU.0000000000001314
Chowdhury FU, Scarsbrook AF. Indium‐111 pentetreotide uptake within cerebellar hemangioblastoma in von Hippel‐Lindau syndrome. Clin Nucl Med. 2008;33(4):294‐296. doi:10.1097/RLU.0b013e3181662bf9
Ambrosini V, Campana D, Allegri V, Opocher G, Fanti S. 68Ga‐DOTA‐NOC PET/CT Detects somatostatin receptors expression in von Hippel‐Lindau cerebellar disease. Clin Nucl Med. 2011;36(1):64‐65. doi:10.1097/RLU.0b013e3181fef14a
Oh JR, Kulkarni H, Carreras C, Schalch G, Min JJ, Baum RP. Ga‐68 somatostatin receptor PET/CT in von Hippel‐Lindau disease. Nucl Med Mol Imaging. 2012;46(2):129‐133. doi:10.1007/s13139‐012‐0133‐0
Mukherjee A, Karunanithi S, Bal C, Kumar R. 68Ga DOTANOC PET/CT aiding in the diagnosis of von Hippel‐Lindau syndrome by detecting cerebellar hemangioblastoma and adrenal pheochromocytoma. Clin Nucl Med. 2014;39(10):920‐921. doi:10.1097/RLU.0000000000000486
Papadakis GZ, Millo C, Sadowski SM, Bagci U, Patronas NJ. Endolymphatic sac tumor showing increased activity on 68Ga DOTATATE PET/CT. Clin Nucl Med. 2016;41(10):783‐784. doi:10.1097/RLU.0000000000001315
Guillermet‐Guibert J, Lahlou H, Cordelier P, Bousquet C, Pyronnet S, Susini C. Physiology of somatostatin receptors. J Endocrinol Invest. 2005;28(suppl 11):5‐9.
Corcos O, Couvelard A, Giraud S, et al. Endocrine pancreatic tumors in von Hippel‐Lindau disease. Pancreas. 2008;37(1):85‐93. doi:10.1097/MPA.0b013e31815f394a
Qian ZR, Li T, Ter‐Minassian M, et al. Association between somatostatin receptor expression and clinical outcomes in neuroendocrine tumors. Pancreas. 2016;45(10):1386‐1393. doi:10.1097/MPA.0000000000000700
Feijtel D, Doeswijk GN, Verkaik NS, et al. Inter and intra‐tumor somatostatin receptor 2 heterogeneity influences peptide receptor radionuclide therapy response. Theranostics. 2021;11(2):491‐505. doi:10.7150/thno.51215
Watson JC, Balster DA, Gebhardt BM, et al. Growing vascular endothelial cells express somatostatin subtype 2 receptors. Br J Cancer. 2001;85(2):266‐272. doi:10.1054/bjoc.2001.1881
Haber MA, Iranmahboob A, Thomas C, Liu M, Najjar A, Zagzag D. ERG is a novel and reliable marker for endothelial cells in central nervous system tumors. Clin Neuropathol. 2015;34(05):117‐127. doi:10.5414/NP300817
Reubi JC. Somatostatin and other peptide receptors as tools for tumor diagnosis and treatment. Neuroendocrinology. 2004;80(SUPPL. 1):51‐56. doi:10.1159/000080742
National Cancer Institute. Belzutifan Approved to Treat Tumors Linked to Inherited Disorder VHL. 2022. Accessed March 28, 2024. https://www.cancer.gov/news‐events/cancer‐currents‐blog/2022/belzutifan‐von‐hippel‐lindau‐disease
Jonasch E, Donskov F, Iliopoulos O, et al. Belzutifan for renal cell carcinoma in von Hippel‐Lindau disease. N Engl J Med. 2021;385(22):2036‐2046. doi:10.1056/NEJMoa2103425
Gomes‐Porras M, Cárdenas‐Salas J, Álvarez‐Escolá C. Somatostatin analogs in clinical practice: a review. Int J Mol Sci. 2020;21(5):1682. doi:10.3390/ijms21051682
Caplin ME, Pavel M, Cwikla JB, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371(3):224‐233. doi:10.1056/nejmoa1316158
Rinke A, Müller HH, Schade‐Brittinger C, et al. Placebo‐controlled, double‐blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group. J Clin Oncol. 2009;27(28):4656‐4663. doi:10.1200/JCO.2009.22.8510
Pyronnet S, Bousquet C, Najib S, Azar R, Laklai H, Susini C. Antitumor effects of somatostatin. Mol Cell Endocrinol. 2008;286(suppl 1‐2):230‐237. doi:10.1016/j.mce.2008.02.002